Sugi Predict

Sugi Predict / Compounds / SCHEMBL4336707

SCHEMBL4336707

SCHEMBL4336707

CN(C)[C@@H]1CCN(c2cc(N3CCN(c4ccccc4C(F)(F)F)CC3)c(F)cc2/C=N/NC(N)=S)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 1/20 0.39
▸ TTR P02766 1/20 0.38
▸ PHGDH O43175 3/20 0.37
▸ EML4 Q9HC35 1/20 0.35
▸ ALK Q9UM73 1/20 0.35
▸ PIM1 P11309 1/20 0.35
▸ PIM3 Q86V86 1/20 0.35
▸ PIM2 Q9P1W9 1/20 0.35
▸ WDR5 P61964 1/20 0.35
▸ MYC P01106 1/20 0.35
▸ GAA P10253 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ LCK P06239 2/20 0.33
▸ KDR P35968 2/20 0.33
▸ TEK Q02763 2/20 0.33
▸ CHEK2 O96017 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336711 1.00 MAOB (0.39) MAOBTTRPHGDHEML4ALK
SCHEMBL4327449 0.91 MAOB (0.44) MAOBPIM1PIM3PIM2MYC
SCHEMBL4327443 0.91 MAOB (0.44) MAOBPIM1PIM3PIM2MYC
SCHEMBL4331101 0.91 MAOB (0.37) MAOBEML4ALKWDR5RBP4
SCHEMBL4331104 0.91 MAOB (0.37) MAOBEML4ALKWDR5RBP4
SCHEMBL4336331 0.91 TRPV1 (0.42) PHGDHGAARBP4
SCHEMBL4336328 0.91 TRPV1 (0.42) PHGDHGAARBP4
SCHEMBL4330711 0.90 MAOB (0.40) MAOBPIM1PIM3PIM2WDR5
SCHEMBL4330708 0.90 MAOB (0.40) MAOBPIM1PIM3PIM2WDR5
SCHEMBL4331454 0.90 MAOB (0.40) MAOBPIM1PIM3PIM2MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAOB 2762/4885TTR 400/4885PHGDH 2500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.